Trial Profile
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Aug 2023
Price :
$35
*
At a glance
- Drugs Ilginatinib (Primary)
- Indications Myelofibrosis; Polycythaemia vera; Thrombocytosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors NS Pharma
- 08 Aug 2023 According to a NS Pharma media release, the European Commission (EC) has granted Orphan Drug Designation to NS-018 (ilginatinib) an oral, selective JAK2 inhibitor which is being investigated for the treatment of myelofibrosis (MF).
- 08 Aug 2023 According to a NS Pharma media release, in the US, NS-018 received Orphan Drug Designation by the U.S. Food and Drug Administration in December 2022.
- 08 Mar 2021 Status changed from active, no longer recruiting to completed.